[{"address1": "180 North LaSalle Street", "address2": "Suite 1600", "city": "Chicago", "state": "IL", "zip": "60601", "country": "United States", "phone": "844 445 5704", "website": "https://www.xerispharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.", "fullTimeEmployees": 377, "companyOfficers": [{"maxAge": 1, "name": "Mr. Paul R. Edick", "age": 67, "title": "Chairman & CEO", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 1206766, "exercisedValue": 0, "unexercisedValue": 590310}, {"maxAge": 1, "name": "Mr. John P. Shannon", "age": 61, "title": "President & COO", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 918153, "exercisedValue": 0, "unexercisedValue": 148377}, {"maxAge": 1, "name": "Mr. Steven M. Pieper", "age": 45, "title": "Chief Financial Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 681142, "exercisedValue": 0, "unexercisedValue": 15586}, {"maxAge": 1, "name": "Ms. Beth P. Hecht J.D.", "age": 59, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 695443, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kenneth E. Johnson Pharm. D., Pharm.D.", "age": 60, "title": "Senior VP of Global Development & Medical Affairs", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 596967, "exercisedValue": 0, "unexercisedValue": 31173}, {"maxAge": 1, "name": "Ms. Allison  Wey", "title": "Senior Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin  McCulloch", "title": "Chief Commercial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.05, "open": 2.03, "dayLow": 1.99, "dayHigh": 2.05, "regularMarketPreviousClose": 2.05, "regularMarketOpen": 2.03, "regularMarketDayLow": 1.99, "regularMarketDayHigh": 2.05, "beta": 1.204, "forwardPE": -11.111111, "volume": 583652, "regularMarketVolume": 583652, "averageVolume": 1757472, "averageVolume10days": 1462010, "averageDailyVolume10Day": 1462010, "bid": 2.0, "ask": 2.01, "bidSize": 100, "askSize": 200, "marketCap": 296512000, "fiftyTwoWeekLow": 1.46, "fiftyTwoWeekHigh": 3.26, "priceToSalesTrailing12Months": 1.7303859, "fiftyDayAverage": 1.9652, "twoHundredDayAverage": 2.14285, "currency": "USD", "enterpriseValue": 485267104, "profitMargins": -0.37583, "floatShares": 144123778, "sharesOutstanding": 148256000, "sharesShort": 9640281, "sharesShortPriorMonth": 8984970, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.065, "heldPercentInsiders": 0.0242, "heldPercentInstitutions": 0.42689, "shortRatio": 7.54, "shortPercentOfFloat": 0.066599995, "impliedSharesOutstanding": 148256000, "bookValue": -0.062, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -64401000, "trailingEps": -0.47, "forwardEps": -0.18, "enterpriseToRevenue": 2.832, "enterpriseToEbitda": -14.846, "52WeekChange": -0.26523298, "SandP52WeekChange": 0.28043115, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "XERS", "underlyingSymbol": "XERS", "shortName": "Xeris Biopharma Holdings, Inc.", "longName": "Xeris Biopharma Holdings, Inc.", "firstTradeDateEpochUtc": 1529587800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8f5f7125-cc84-3c21-a68b-9d3090e24887", "messageBoardId": "finmb_105901792", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.0, "targetHighPrice": 6.0, "targetLowPrice": 3.0, "targetMeanPrice": 4.58, "targetMedianPrice": 4.75, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 87352000, "totalCashPerShare": 0.589, "ebitda": -32686000, "totalDebt": 268695008, "quickRatio": 1.707, "currentRatio": 2.371, "totalRevenue": 171356000, "revenuePerShare": 1.237, "returnOnAssets": -0.08545, "returnOnEquity": -6.1716304, "freeCashflow": -47130876, "operatingCashflow": -41186000, "revenueGrowth": 0.224, "grossMargins": 0.82903, "ebitdaMargins": -0.19075, "operatingMargins": -0.35053003, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-21"}]